PF-04447943
- Generic Name
- PF-04447943
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25N7O2
- CAS Number
- 1082744-20-4
- Unique Ingredient Identifier
- 7N969W8Y4O
- Background
PF-04447943 has been investigated for the treatment of Alzheimer's Disease.
A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects
- First Posted Date
- 2016-05-30
- Last Posted Date
- 2018-12-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT02785770
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2017-12-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT02114203
- Locations
- 🇺🇸
University of Illinois at Chicago Clinical Research Center, Chicago, Illinois, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
🇺🇸University of Illinois Hospital and Health Sciences System, Chicago, Illinois, United States
A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Of PF-04447943 When Administered With Donepezil To Healthy Volunteer Subjects
- First Posted Date
- 2010-04-02
- Last Posted Date
- 2010-08-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT01097876
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT00988598
- Locations
- 🇺🇸
MD Clinical, Hallandale Beach, Florida, United States
🇺🇸Glendale Adventist Medical Center, Glendale, California, United States
🇺🇸University of Florida - Center for Clinical Trials Research, Gainesville, Florida, United States
Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 17
- Registration Number
- NCT00959803
- Locations
- 🇺🇸
Pfizer Investigational Site, Glendale, California, United States
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 191
- Registration Number
- NCT00930059
- Locations
- 🇺🇸
Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States
🇺🇸Neurocare, Inc., Newton, Massachusetts, United States
🇨🇦Medical Arts Health Research Group, Kelowna, British Columbia, Canada
A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult Participants
- First Posted Date
- 2009-04-22
- Last Posted Date
- 2009-07-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT00886093
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2009-06-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00832052
- Locations
- 🇺🇸
Pfizer Investigational Site, Gainesville, Florida, United States
A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2009-02-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT00736528
- Locations
- 🇺🇸
Pfizer Investigational Site, Gainesville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.